Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
12 July 1996Website:
http://aimimmuno.comNext earnings report:
15 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 23:58:04 GMTDividend
Analysts recommendations
Institutional Ownership
AIM Latest News
Pantheon Resources PLC (AIM:PANR, OTCQX:PTHRF) has hired an American investor relations firm as it seeks to woo US investors, ahead of the next wave of progress at the AIM-quoted firm's Alaskan oil and gas assets. It has appointed MZ Group to lead its investor relations efforts in the US.
The potential removal of inheritance tax relief on AIM-listed shares in the upcoming UK Budget has sparked concerns among investors, with many viewing the change as "painful" and "unnecessary". However, Marcus Stuttard, head of AIM and UK primary markets at the London Stock Exchange, doesn't expect Chancellor Rachel Reeve's impending tax raid to be a death knell for the junior market.
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR TO BE TRANSMITTED, DISTRIBUTED TO, OR SENT BY, ANY NATIONAL OR RESIDENT OR CITIZEN OF ANY SUCH COUNTRIES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION MAY CONTRAVENE LOCAL SECURITIES LAWS OR REGULATIONS. CASCAIS, PORTUGAL / ACCESSWIRE / October 18, 2024 / Pulsar Helium Inc. (AIM:PLSR)(TSXV:PLSR)(OTCQB:PSRHF) ("Pulsar" or the "Company"), the helium project development company, is pleased to announce that its common shares will commence trading today, 18 October 2024, on the AIM market of the London Stock Exchange plc ("AIM") (the "Admission").
SINGAPORE, Oct. 15, 2024 (GLOBE NEWSWIRE) -- BitFuFu Inc., (“BitFuFu” or “the Company”) (NASDAQ: FUFU), a fast-growing digital asset mining service and world-leading cloud-mining service provider, today announced that it will attend the AIM Summit Dubai 2024, which will take place from October 21 to 22, 2024, at Jumeirah Emirates Towers.
Pulsar Helium Inc (TSXV:PLSR, OTC:PSRHF), an explorer focused on acreage in Minnesota, has confirmed the completion of a £3.88 million (C$7 million) equity raise, ahead of joining the AIM market later this week. Including a prior pre-IPO raise of £1.13 million, Pulsar will come to the London market holding around £5 million of cash.
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR TO BE TRANSMITTED, DISTRIBUTED TO, OR SENT BY, ANY NATIONAL OR RESIDENT OR CITIZEN OF ANY SUCH COUNTRIES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION MAY CONTRAVENE LOCAL SECURITIES LAWS OR REGULATIONS. CASCAIS, PORTUGAL / ACCESSWIRE / October 15, 2024 / Pulsar Helium Inc. (AIM:PLSR)(TSXV:PLSR)(OTCQB:PSRHF) ("Pulsar" or the "Company"), the helium project development company, is pleased to announce that it has conditionally raised £3.875 million (C$7 million) (before expenses), through a placing of new common shares with new and existing investors (the "Fundraising") and is today publishing an AIM admission document ("Admission Document") in connection with the admission of the enlarged share capital of the Company to trading on the AIM Market of the London Stock Exchange plc ("AIM")("Admission").
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, October 2nd at 4:00 PM ET Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, October 2nd at 4:00 PM ET
Jersey Oil and Gas PLC (AIM:JOG, OTC:JYOGF) chief executive Andrew Benitz, in today's interim results statement, highlighted February's farm-out to Serica Energy as testament to the quality of the GBA asset, a project the AIM-quoted firm nurtured from inception. It added to prior deal with NEO Energy, and, ensured Jersey was fully funded for its remaining 20% interest in the Buchan development project.
Occupational health specialist Optima Health PLC will begin life as a stand-alone company on the AIM section of the London Stock Exchange later this month after being spun out of Marlow PLC. The Glasgow-based firm said it has no intention to raise new capital in connection with admission.
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR TO BE TRANSMITTED, DISTRIBUTED TO, OR SENT BY, ANY NATIONAL OR RESIDENT OR CITIZEN OF ANY SUCH COUNTRIES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION MAY CONTRAVENE LOCAL SECURITIES LAWS OR REGULATIONS. This announcement is an advertisement and not an admission document or a prospectus and does not constitute or form part of an offer to sell or issue or a solicitation of an offer to subscribe for or buy any securities nor should it be relied upon in connection with any contract or commitment whatsoever in any jurisdiction.
- 1(current)
- 2
What type of business is AIM ImmunoTech?
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
What sector is AIM ImmunoTech in?
AIM ImmunoTech is in the Healthcare sector
What industry is AIM ImmunoTech in?
AIM ImmunoTech is in the Biotechnology industry
What country is AIM ImmunoTech from?
AIM ImmunoTech is headquartered in United States
When did AIM ImmunoTech go public?
AIM ImmunoTech initial public offering (IPO) was on 12 July 1996
What is AIM ImmunoTech website?
https://aimimmuno.com
Is AIM ImmunoTech in the S&P 500?
No, AIM ImmunoTech is not included in the S&P 500 index
Is AIM ImmunoTech in the NASDAQ 100?
No, AIM ImmunoTech is not included in the NASDAQ 100 index
Is AIM ImmunoTech in the Dow Jones?
No, AIM ImmunoTech is not included in the Dow Jones index
When was AIM ImmunoTech the previous earnings report?
No data
When does AIM ImmunoTech earnings report?
The next expected earnings date for AIM ImmunoTech is 15 November 2024